The tuberculosis (TB) diagnostics market size was worth USD 2.39 Billion in 2023 and is expected to reach USD 3.80 Billion by 2032 and grow at a CAGR of 5.29% over the forecast period of 2024-2032.
Get More Information on Tuberculosis (TB) Diagnostics Market - Request Sample Report
The report includes a comprehensive analysis of healthcare facility loan distribution and its impact on diagnostic infrastructure, especially in low- and middle-income countries. The report covers the adoption of advanced diagnostic technologies and provides equipment lifecycle data relevant to TB testing systems. The report also studies recent mergers and acquisitions, which are shaping landscape of medical diagnostics financing. In addition, as of 2023, the report highlights the surge in the demand for tailored financing solutions to boost access to TB diagnostics and innovative trends in research and development across various diagnostic types globally. Tuberculosis (TB) diagnostics shows how the technological, financial, and strategic dynamics are propelling the market expansion globally.
The market expansion in the U.S. was valued at USD 309 Million in 2023 and is projected to be valued at USD 526 Million by 2032, expanding at a CAGR of 6.09% during the forecast period.
In 2023, the U.S. held the largest tuberculosis (TB) diagnostics market share due to its advanced diagnostic technologies, strong government commitments, and robust healthcare infrastructure for surveillance and controlling TB. In the U.S., the tuberculosis (TB) diagnostics market growth is driven by the large implementation of nucleic acid amplification tests (NAATs), strong investments in public health programs via agencies including the NIH and CDC, and availability of TB test kits approved by the U.S.-FDA. In addition, the growth of the market is also propelling owing to the presence of the leading diagnostic players and ongoing research collaborations with academic institutions, further boosting innovation and the adoption of faster and more accurate TB diagnostic tools.
Drivers:
Rising Government Funding and Public Health Initiatives to Accelerate Market Growth
The surging government funding and synchronized public health efforts, particularly targeting the eradication of tuberculosis (TB) is driving the tuberculosis (TB) diagnostics market growth. The high adoption of different national TB programs and international initiatives, such as End TB Strategy by WHO has increased the implementation of TB screening campaigns and upgrades in diagnostics infrastructure on a large scale. In the U.S., agencies including the NIH and CDC have substantially raised investments to control TB spread, further allowing broader access to advanced diagnostics, such as interferon-gamma release assays (IGRAs) and nucleic acid amplification tests (NAATs). The developing nations are also receiving both technical and financial support from global organizations to tackle the spread of tuberculosis (TB), improving early detection and treatment outcomes. These strategic efforts are raising the demand for effective and rapid tuberculosis (TB) diagnostic tools, which makes the involvement of public-sector companies a major driver of the market growth globally.
Restraints:
High Advanced TB Diagnostic Tools Costs is Hampering their Accessibility in Low-resource Healthcare Settings
As advanced technologies have substantially amended the speed and accuracy and accuracy of tuberculosis TB diagnostics, the high cost of these diagnostic tools act as a major restraint hampering market growth, specifically in the low- and middle-income countries. Techniques, such as line probe assays, NAATs, and next-generation sequencing offer superior diagnostic performance but they have high maintenance costs, skilled professionals, and expensive instruments. This creates a discrepancy in TB detection capabilities between resource-limited regions having high burden of TB and high-income nations. Furthermore, the lack of reimbursement policies for latest diagnostic procedures in several healthcare systems also limits the adoption of these diagnostic tools. Regardless of the support from the government and donor in several areas, the deployment of these advanced diagnostic tools is still challenging due to limited funds in the underfunded healthcare settings, raising a critical challenge to reach the goal of global TB control and hindering market growth in the underdeveloped regions.
Opportunities:
Emerging Point-of-Care TB Diagnostic Solutions Present Lucrative Opportunities in Remote and Rural Areas
The development of affordable and portable point-of-care (POC) diagnostic solutions offers a major opportunity in the TB diagnostics market, especially for regions with limited laboratory infrastructure. These tools can be deployed directly at community health centers, further allowing for immediate treatment decisions and early detection of the disease even in remote regions. The high adoption of innovations, such as microfluidic devices, smart-phone integrated diagnostics, and paper-based biosensors for tuberculosis (TB) detection, with many products are already in the development stages. Different organizations, including the Bill & Melinda Gates Foundation and FIND are funding research to propel the launch of low-cost and scalable TB POC technologies globally. The demand for POC diagnostics is projected to increase as the global health policies are emphasizing the decentralized care and equitable access, further driving the market expansion.
Challenges:
Infrastructure Challenges and Lack of Skilled Laboratory Professionals are Limiting the Accuracy of TB diagnostic in Developing Nations
The lack of trained or skilled laboratory professionals and inadequate diagnostic infrastructure in several high-TB-burden regions are some of the major challenges affecting the market expansion globally. Complex tests, including molecular assays and culture-based detection significantly require skilled personnel and sophisticated laboratory settings, which are mainly absent in the rural and underdeveloped regions. In addition, poor maintenance of diagnostic equipment, inconsistent sample collection practices, and lack of high-quality reagents, negatively affects the test results, further decreasing the disease control efforts. The inability to safeguard the quality and standardization across multiple testing sites severely impedes the patient outcomes and diagnostic accuracy, even with the availability of advanced technologies. To overcome this challenge, a systemic investment in building the healthcare capacity, enhanced logistics for ensuring reliable TB detection, and continuous training programs across all the healthcare ecosystem levels.
By Type
Based on type, the market is classified into detection of latent infection (skin test & IGRA), phage assay, detection of drug resistance (DST), nucleic acid testing, radiographic method, cytokine detection assay, and others. In 2023, the market is being dominated by the latent infection detection segment with a share at around 43%. The segment’s growth is attributed to its growing use in addressing critical need for asymptomatic carriers’ identification that can later provide active disease. The interferon-gamma release assays (IGRAs) and tuberculin skin tests (TSTs) are majorly used owing to their proven sensitivity and specificity in mycobacterium tuberculosis infection detection before symptoms arise. Public health programs in both high‑ and low‑burden nations are prioritizing the latent TB screening process among the high‑risk groups, including immunocompromised patients, healthcare workers, and people having close contacts with active TB patients to prevent TB transmission and decrease disease incidence.
By End-Use
On the basis of end-use, the market is trifurcated into diagnostic laboratories, hospitals & clinics, and others. The hospitals & clinics segment dominated the market in terms of share at around 47% in 2023. The segment’s growth is driven by the vital role of hospitals in administering vaccinations for Hepatitis B during birth and during postnatal care and regular medical services. Hospitals, as the first service contact point for newborns, routinely administer hepatitis B birth dose as part of national immunization programs especially in countries with very high birth rates and good institutional delivery coverage. Likewise, hospitals have the facilities and staff to store and administer vaccines and monitor for any post-vaccination adverse events and must abide by safety protocols set by the government. Increased awareness about nosocomial infections and preventive healthcare, in addition to adults and healthcare workers, are now choosing to be vaccinated for hepatitis B during routine hospital visits or pre-employment screenings. This, coupled with greater patient confidence for hospital-based care has cemented hospitals as the preferred center to the distribution and administration, thereby capturing the leading share of the market globally.
In 2023, Asia Pacific held the largest market share in the tuberculosis (tb) diagnostics market around 39%. The growth is driven by its high disease burden, growing healthcare investments, and rapid adoption of diagnostic technologies across emerging economies. Countries, such as India, China, Indonesia, and the Philippines account for a significant portion of global TB cases, prompting strong governmental and international efforts to scale up early detection and treatment. National programs such as India’s National TB Elimination Programme (NTEP) and China's expanded public health strategies have accelerated the deployment of advanced diagnostic tools, including GeneXpert systems and digital chest X-rays. Additionally, Asia Pacific benefits from an expanding network of public-private partnerships and support from global agencies such as WHO and the Global Fund. The region’s large population base, rising awareness, and ongoing healthcare infrastructure development collectively make it the dominant contributor to the global TB diagnostics market.
For instance, Indonesia reported over 1 million TB cases in 2023, an increase from approximately 820,000 cases in 2020, with TB-related deaths reaching around 134,000 in 2022, the second highest globally after India. Similarly, the Philippines' Department of Health recorded 446,478 TB cases as of September 30, 2023.
North America held a significant share in the tuberculosis (TB) diagnostics market owing its advanced healthcare infrastructure, high awareness levels, and strong government-led TB control programs. The U.S. and Canada have established comprehensive public health surveillance systems and prioritize early detection, routine screening, and preventive strategies for high-risk populations, such as immigrants, immunocompromised individuals, and healthcare workers. The U.S. Centers for Disease Control and Prevention (CDC) actively funds TB control efforts, including the use of advanced diagnostic methods, such as nucleic acid amplification tests (NAATs) and interferon-gamma release assays (IGRAs). Additionally, the presence of major diagnostic technology providers and consistent investments in research and development enhance regional capabilities. Furthermore, stringent regulatory guidelines and reimbursement policies ensure the adoption of quality diagnostic tools, making North America a key contributor to the global tuberculosis (TB) diagnostics market expansion.
Akonni Biosystems Inc. (TruTip Sample Prep, TB Multi-Drug Resistance Panel)
Alere Inc. (Alere Determine TB LAM Ag, Alere qTB)
Par Pharmaceutical (Isoniazid Tablets, Rifampin Capsules)
Lionex GmbH (LIONEX TB LAM Rapid Test, TB IgG ELISA)
Creative Diagnostics (TB Ag85 ELISA Kit, TB ESAT-6 Recombinant Protein)
Abbott Laboratories (RealTime MTB, m2000 System)
BioMerieux SA (VIDAS TB IGRA, BacT/ALERT 3D)
Cepheid (GeneXpert MTB/RIF, GeneXpert MTB/XDR)
Hologic Inc. (Panther Fusion System, Aptima MTB Assay)
F. Hoffmann-La Roche Ltd. (COBAS MTB, COBAS TaqMan MTB-RIF)
Qiagen (QuantiFERON-TB Gold Plus, QIAstat-Dx Analyzer)
BD (Becton, Dickinson and Company) (BD MAX MDR-TB, BD MGIT 960)
Siemens Healthineers (CLINITEK Status+, Dimension EXL)
Thermo Fisher Scientific (TaqMan TB Detection Kit, Ion Torrent NGS)
Bio-Rad Laboratories Inc. (Platelia TB ELISA, BioPlex 2200 System)
Luminex Corporation (xMAP Technology, ARIES System)
PerkinElmer Inc. (DELFI Diagnostics, TB PCR Detection Kit)
Zhejiang Orient Gene Biotech Co. Ltd. (TB Rapid Test Cassette, TB Antigen Detection Kit)
Tosoh Corporation (AIA-900 Analyzer, Enzyme Immunoassay Kit for TB)
Oxford Immunotec (T-SPOT.TB, T-Cell Select Kit)
In 2024, QIAGEN launched the QIAseq xHYB Mycobacterium Tuberculosis Panel, a culture-independent solution for whole genome sequencing directly from patient samples, which significantly accelerates diagnostic timelines and enhances real-time tracking of tuberculosis outbreaks.
In 2023, Siemens Healthineers and Global Fund partnered to promote the integration of artificial intelligence into chest X-ray screening for tuberculosis to enhance diagnostic accuracy and operational efficiency in TB detection.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 2.39 Billion |
| Market Size by 2032 | USD3.80Billion |
| CAGR | CAGR of5.29 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Others) • By End Use (Diagnostic Laboratories, Hospitals & Clinics, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Akonni Biosystems Inc., Alere Inc., Par Pharmaceutical, Lionex GmbH, Creative Diagnostics, Abbott Laboratories, BioMerieux SA, Cepheid, Hologic Inc., F. Hoffmann-La Roche Ltd., Qiagen, BD (Becton, Dickinson and Company), Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Luminex Corporation, PerkinElmer Inc., Zhejiang Orient Gene Biotech Co. Ltd., Tosoh Corporation, Oxford Immunotec |
Ans: The tuberculosis (TB) diagnostics market was valued at USD 2.39 Billion in 2023.
Ans: The expected CAGR of the global tuberculosis (TB) diagnostics market during the forecast period is 5.29%
Ans: Diagnostic laboratories will grow rapidly in the tuberculosis (TB) diagnostics market from 2024 to 2032.
Ans: Rising government funding and public health initiatives to accelerate the global tuberculosis (TB) diagnostics market growth.
Ans: Asia Pacific led the tuberculosis (TB) diagnostics market in the region with the highest revenue share in 2023.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Healthcare Facility Loan Distribution
5.2 Technology Adoption & Equipment Lifecycle Data
5.3 Mergers & Acquisitions in Medical Financing Sector
5.4 Growth in Demand for Financing Solutions
5.5 Innovation and R&D, Type, 2023
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Tuberculosis (TB) Diagnostics Market Segmentation By Type
7.1 Chapter Overview
7.2 Detection of Latent Infection (Skin Test & IGRA)
7.2.1 Detection of Latent Infection (Skin Test & IGRA) Trends Analysis (2020-2032)
7.2.2 Detection of Latent Infection (Skin Test & IGRA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Phage Assay
7.3.1 Phage Assay Market Trends Analysis (2020-2032)
7.3.2 Phage Assay Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Detection of Drug Resistance (DST)
7.4.1 Detection of Drug Resistance (DST) Market Trends Analysis (2020-2032)
7.4.2 Detection of Drug Resistance (DST) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Nucleic Acid Testing
7.5.1 Nucleic Acid Testing Market Trends Analysis (2020-2032)
7.5.2 Nucleic Acid Testing Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Radiographic Method
7.6.1 Radiographic Method Market Trends Analysis (2020-2032)
7.6.2 Radiographic Method Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Cytokine Detection Assay
7.7.1 Cytokine Detection Assay Market Trends Analysis (2020-2032)
7.7.2 Cytokine Detection Assay Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Others
7.8.1 Others Market Trends Analysis (2020-2032)
7.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Tuberculosis (TB) Diagnostics Market Segmentation By End Use Industry
8.1 Chapter Overview
8.2 Diagnostic Laboratories
8.2.1 Diagnostic Laboratories Market Trends Analysis (2020-2032)
8.2.2 Diagnostic Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Hospitals & Clinics
8.3.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
8.3.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.4 North America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.5.2 USA Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.6.2 Canada Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.7.2 Mexico Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts By Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts By End Use Industry (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Tuberculosis (TB) Diagnostics Market Estimates and Forecasts By Type (2020-2032) (USD Billion)
9.3.1.5.2 Poland Tuberculosis (TB) Diagnostics Market Estimates and Forecasts By End Use Industry (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.6.2 Romania Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.5.2 Germany Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.6.2 France Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.7.2 UK Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.8.2 Italy Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.12.2 Austria Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 China Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 India Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.5.2 Japan Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.6.2 South Korea Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.2.7.2 Vietnam Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.8.2 Singapore Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.9.2 Australia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.5.2 UAE Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.4 Africa Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.4 Latin America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.5.2 Brazil Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.6.2 Argentina Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.7.2 Colombia Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Tuberculosis (TB) Diagnostics Market Estimates and Forecasts, By End Use Industry (2020-2032) (USD Billion)
10.1 Akonni Biosystems Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Alere Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Par Pharmaceutical
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Lionex GmbH
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Creative Diagnostics
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Abbott Laboratories
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 BioMerieux SA
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Cepheid, Hologic Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 F. Hoffmann-La Roche Ltd
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Tosoh Corporation
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
Detection of Latent Infection (Skin Test & IGRA)
Phage Assay
Detection of Drug Resistance (DST)
Nucleic Acid Testing
Radiographic Method
Cytokine Detection Assay
Others
By End Use
Diagnostic Laboratories
Hospitals & Clinics
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
Autoinjectors Market size was valued at USD 8.42 billion in 2023 and is projected to reach USD 28.42 billion by 2032, with a CAGR of 14.5% from 2024 to 2032.
The Ventricular Assist Device Market Size was USD 1.6 Billion in 2023 and is projected to grow to USD 3.3 Billion by 2032, with a CAGR of 8.8%.
The Consumer Healthcare market was valued at USD 302.87 billion in 2023 and is expected to reach USD 588.68 billion by 2032 and grow at a CAGR of 7.68% over the forecast period of 2024-2032.
The Healthcare Data Storage Market Size was valued at USD 4.7 Bn in 2023 and will reach to USD 15.54 Bn by 2032 and grow at a CAGR of 14.23% by 2024-2032.
The Heart Attack Diagnostics Market size was valued at USD 11.01 billion in 2023, projected to reach USD 21.38 billion by 2032, growing at a CAGR of 7.64%.
The Artificial Heart Market was valued at USD 2.87 billion in 2023 and is expected to reach USD 7.55 billion by 2032, growing at a CAGR of 11.36% over the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
